Therapeutic targeting of cell cycle checkpoint aberrations in pancreatic cancer: personalised medicine in action [ 2015 - 2017 ]

Research Grant

Researchers: Dr Marina Pajic (Principal investigator) ,  Dr Andrew Burgess ,  Dr Paul Timpson ,  Prof Anthony Gill ,  Prof Stephen Clarke

Brief description Less than 5% of people with pancreatic cancer (PC) survive 5 years, and the odds of patients beating this disease have remained unchanged for 50 years. Consequently, there is an urgent need to develop novel treatment approaches for this highly aggressive cancer. Our study aims to define novel therapeutic strategies for PC utilising specific anti-proliferative therapies and a personalised “companion biomarker” directed strategy.

Funding Amount $AUD 634,354.24

Funding Scheme Project Grants

Notes Standard Project Grant